Thymosin Beta-4 (TB4): The Parent Molecule, Not the TB-500 Fragment

Thymosin Beta-4 (TB4) is a 43-amino-acid naturally occurring peptide present in most cell types. It is the parent molecule of TB-500, which is a synthetic fragment of the active site. The two are often discussed interchangeably in self-experimenter circles, but they are not the same compound. This post is about full-length TB4. If you are running the fragment, the practical protocol shape is similar but the molecule is different.

What it does

TB4 is involved in actin sequestration, cytoskeletal organization, and a long list of downstream effects: cell migration, angiogenesis, wound healing, and cardioprotection in animal models. Clinical trials in humans have explored cardiac repair after infarction and corneal wound healing.

The fragment TB-500 was developed because the active site is what matters in many of these processes, and the fragment is cheaper to synthesize. Whether full-length TB4 offers benefits beyond what the fragment delivers in self-experimenter use is genuinely unknown.

Typical protocol shape

Reported patterns:

• Loading phase of several weeks, often 1 to 2 administrations per week
• Maintenance at lower frequency (every 1 to 2 weeks) if continued
• Subcutaneous administration is standard

Half-life is long compared to BPC-157, so daily dosing is unnecessary.

What to track daily

• Sleep quality and duration
• Recovery score on waking (1 to 10)
• Pain and stiffness by site (1 to 10)
• Training load
• Side effects, particularly any flu-like symptoms in the first week
• Mood

What to track weekly

• Range of motion at affected joints
• Pain-free reps or load at a benchmark lift
• Body weight
• Photo of any visible injury site

Bloodwork worth doing

For a recovery-focused TB4 cycle, routine labs (CBC, CMP) before and after a 12-week cycle give a general safety read. There is no established TB4-specific biomarker to track in serum at the self-experimenter level.

Realistic expectations

Recovery peptides almost never deliver dramatic first-week effects. The honest evaluation window is 6 to 12 weeks of consistent dosing plus consistent logs. If a single injection seems to fix a long-standing problem, that is almost certainly placebo plus regression to the mean. Peptide IA exists specifically because the only way to tell signal from vibe is week-over-week data.

Common mistakes

• Confusing TB4 with TB-500. They are related but not identical. Log which one you are actually using.
• Stacking with BPC-157 from day one. You learn nothing about either compound that way.
• No baseline. Without two to four weeks of pre-cycle logs, "I feel better" is unfalsifiable.
• Stopping at week 4. Most reported benefits are described over longer windows.

A tracking template

• Weeks minus 4 to 0: baseline, no peptide
• Weeks 1 to 4: loading dose, daily log
• Weeks 5 to 12: maintenance dose, daily log
• Weeks 13 to 16: washout, daily log
• Compare windows in Peptide IA to see if effects persisted

Safety notes

Human safety data on long-term self-experimenter use of full-length TB4 is limited. Discuss with a physician, particularly if you have a history of cancer, given the angiogenic and cell-migration effects in research models.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.